EGFL8
Epidermal growth factor-like protein 8
Also known as: C6orf8, EGFL8_HUMAN, NG3
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q99944
- Gene
- EGFL8
- Ensembl
- ENSG00000241404
- Chromosome
- 6
- Canonical length
- 293 aa
- Protein class
- Metabolic proteins, Predicted secreted proteins
- Subcellular location
- Nuclear speckles,Vesicles
- Secretome location
- Secreted - unknown location
OverviewNCBI Gene
Predicted to enable signaling receptor binding activity. Predicted to be involved in vasculogenesis. Predicted to be active in cell surface and extracellular region. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
293 residues, UniProt reviewed canonical sequence.
>Q99944|EGFL8
1 MGSRAELCTL LGGFSFLLLL IPGEGAKGGS LRESQGVCSK QTLVVPLHYN ESYSQPVYKP
61 YLTLCAGRRI CSTYRTMYRV MWREVRREVQ QTHAVCCQGW KKRHPGALTC EAICAKPCLN
121 GGVCVRPDQC ECAPGWGGKH CHVDVDECRT SITLCSHHCF NTAGSFTCGC PHDLVLGVDG
181 RTCMEGSPEP PTSASILSVA VREAEKDERA LKQEIHELRG RLERLEQWAG QAGAWVRAVL
241 PVPPEELQPE QVAELWGRGD RIESLSDQVL LLEERLGACS CEDNSLGLGV NHRLocalizationUniProt · AlphaFold · HPA
Whether an antibody against EGFL8 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.48
- Highest tissue expression
- 32 nTPM
Expression across tissuesHPA
Tissue
- ovary: 32 nTPM
- cervix: 23 nTPM
- colon: 20 nTPM
- kidney: 18 nTPM
- fallopian tube: 18 nTPM
- vagina: 17 nTPM
Single-cell type
- astrocytes: 15 nCPM
- bergmann glia: 14 nCPM
- ependymal cells: 13 nCPM
- choroid plexus epithelial cells: 10 nCPM
- oligodendrocytes: 9.5 nCPM
- oligodendrocyte progenitor cells: 8.6 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- choroid plexus: 2.4 nTPM
- thalamus: 2.4 nTPM
- hippocampal formation: 2.1 nTPM
- hypothalamus: 2.1 nTPM
- medulla oblongata: 2 nTPM
- midbrain: 1.9 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.17
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.77
- DepMap mean gene effect
- 0.14
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads EGFL8 as an antibody target. Whether an autoantibody or antibody against EGFL8 could matter depends on whether native EGFL8 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
EGFL8 is annotated as secreted, so native EGFL8 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label EGFL8 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...